View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPharnext S.C.A 過去の業績過去 基準チェック /06Pharnext S.C.Aの収益は年間平均-7.9%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間13.3% 11.3%割合で 減少しています。主要情報-7.91%収益成長率n/aEPS成長率Biotechs 業界の成長-14.59%収益成長率-11.34%株主資本利益率n/aネット・マージン-16,004.27%前回の決算情報31 Dec 2023最近の業績更新Reported Earnings • Oct 18First half 2022 earnings releasedFirst half 2022 results: Net loss: €19.1m (loss widened 41% from 1H 2021). Revenue is forecast to stay flat during the next 2 years compared to a 17% growth forecast for the Biotechs industry in Germany.Reported Earnings • Oct 16First half 2021 earnings releasedFirst half 2021 results: Net loss: €13.6m (loss widened 49% from 1H 2020).Reported Earnings • Apr 30Full year 2020 earnings releasedFull year 2020 results: Net loss: €21.6m (loss narrowed 7.5% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1すべての更新を表示Recent updatesNew Risk • Jul 05New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: €172k (US$186k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (6,663% average daily change). Negative equity (-€32m). Earnings have declined by 7.9% per year over the past 5 years. Revenue is less than US$1m (€172k revenue, or US$186k). Market cap is less than US$10m (€869 market cap, or US$940).お知らせ • May 09Pharnext SA, Annual General Meeting, Jun 10, 2024Pharnext SA, Annual General Meeting, Jun 10, 2024. Location: 14 rue de la republique, suresnes FranceBoard Change • Feb 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of the Supervisory Board Guy-Charles de la Horie was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 01Pharnext SA announced that it has received €41.188458 million in fundingPharnext SA announces private placement of 30,783,601,087 shares for an issue price of €0.001338 per shares for gross proceeds of €41,188,458 on January 31, 2024.Board Change • Jan 22No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of the Supervisory Board Guy-Charles de la Horie was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Jan 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€24m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€24m free cash flow). Share price has been highly volatile over the past 3 months (405% average daily change). Negative equity (-€31m). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€156 market cap, or US$170). Minor Risk Revenue is less than US$5m (€1.8m revenue, or US$2.0m).New Risk • Dec 27New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (367% average daily change). Negative equity (-€31m). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€156 market cap, or US$173). Minor Risk Revenue is less than US$5m (€1.8m revenue, or US$2.0m).お知らせ • Jan 04Pharnext Strengthens Its Senior Leadership Team with the Appointment of Scott Johnson as VP, Head of QualityPharnext SA announces the appointment of Scott Johnson as VP, Head of Quality. This appointment further strengthens the Company's Senior Leadership Team. Scott has more than 15 years of experience in quality management and compliance within the healthcare sector. He joins from Oyster Point Pharma, where he was Head of Quality Assurance. There, he established and implemented a comprehensive quality management system and oversaw all quality-related functions during the submission of an NDA application and successful launch of Oyster Point's first commercial product. Prior to Oyster, Scott served as Director, Quality Assurance at Lupin Pharmaceuticals where he had overall responsibility for quality and compliance. He has also held roles at Johnson & Johnson and Warner Chilcott. Scott has a BA in Organizational Management from the Eastern University, St. David's, PA and previously served in the United States Navy. At Pharnext, Scott will continue to develop and maintain the Company's Quality strategy and ensure its operational execution. He will oversee the Quality activities in the areas of Manufacturing (Good Manufacturing Practices), Laboratory (Good Laboratory Practices) and Clinical (Good Clinical Practices) to ensure compliance with regulatory requirements. Scott will also be responsible for promoting a quality mindset across the Company and working with cross-departmental leadership to ensure the delivery of high-quality products and services.Board Change • Nov 16No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 8 non-independent directors. Director Hugo Brugiere was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.Reported Earnings • Oct 18First half 2022 earnings releasedFirst half 2022 results: Net loss: €19.1m (loss widened 41% from 1H 2021). Revenue is forecast to stay flat during the next 2 years compared to a 17% growth forecast for the Biotechs industry in Germany.Board Change • Apr 27Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 10 non-independent directors. Independent Non-Executive Director Piers Morgan was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Oct 16First half 2021 earnings releasedFirst half 2021 results: Net loss: €13.6m (loss widened 49% from 1H 2020).Reported Earnings • Apr 30Full year 2020 earnings releasedFull year 2020 results: Net loss: €21.6m (loss narrowed 7.5% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1収支内訳Pharnext S.C.A の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:P0X 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 230-284030 Sep 234-255030 Jun 232-3282031 Mar 232-3592031 Dec 227-287030 Sep 225-3271030 Jun 223-3672031 Mar 223-3372031 Dec 214-3172030 Sep 214-2871930 Jun 214-2681831 Mar 213-2481631 Dec 203-2281430 Sep 203-2181330 Jun 203-2081331 Mar 203-2281431 Dec 194-2381530 Sep 194-2481630 Jun 194-2581731 Mar 195-2381731 Dec 187-2171830 Sep 187-2071730 Jun 187-1861731 Mar 185-1961631 Dec 173-2061630 Sep 173-2061630 Jun 174-2051631 Mar 174-1951531 Dec 164-1741430 Sep 164-1641230 Jun 163-1441031 Mar 163-124931 Dec 153-114831 Dec 143-114731 Dec 133-939質の高い収益: P0Xは現在利益が出ていません。利益率の向上: P0Xは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: P0Xは利益が出ておらず、過去 5 年間で損失は年間7.9%の割合で増加しています。成長の加速: P0Xの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: P0Xは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 39.9% ) と比較することは困難です。株主資本利益率高いROE: P0Xの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/11/23 21:06終値2024/08/26 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharnext S.C.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Soo RomanoffEdison Investment Research
Reported Earnings • Oct 18First half 2022 earnings releasedFirst half 2022 results: Net loss: €19.1m (loss widened 41% from 1H 2021). Revenue is forecast to stay flat during the next 2 years compared to a 17% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Oct 16First half 2021 earnings releasedFirst half 2021 results: Net loss: €13.6m (loss widened 49% from 1H 2020).
Reported Earnings • Apr 30Full year 2020 earnings releasedFull year 2020 results: Net loss: €21.6m (loss narrowed 7.5% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1
New Risk • Jul 05New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: €172k (US$186k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (6,663% average daily change). Negative equity (-€32m). Earnings have declined by 7.9% per year over the past 5 years. Revenue is less than US$1m (€172k revenue, or US$186k). Market cap is less than US$10m (€869 market cap, or US$940).
お知らせ • May 09Pharnext SA, Annual General Meeting, Jun 10, 2024Pharnext SA, Annual General Meeting, Jun 10, 2024. Location: 14 rue de la republique, suresnes France
Board Change • Feb 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of the Supervisory Board Guy-Charles de la Horie was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 01Pharnext SA announced that it has received €41.188458 million in fundingPharnext SA announces private placement of 30,783,601,087 shares for an issue price of €0.001338 per shares for gross proceeds of €41,188,458 on January 31, 2024.
Board Change • Jan 22No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of the Supervisory Board Guy-Charles de la Horie was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Jan 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€24m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€24m free cash flow). Share price has been highly volatile over the past 3 months (405% average daily change). Negative equity (-€31m). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€156 market cap, or US$170). Minor Risk Revenue is less than US$5m (€1.8m revenue, or US$2.0m).
New Risk • Dec 27New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (367% average daily change). Negative equity (-€31m). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€156 market cap, or US$173). Minor Risk Revenue is less than US$5m (€1.8m revenue, or US$2.0m).
お知らせ • Jan 04Pharnext Strengthens Its Senior Leadership Team with the Appointment of Scott Johnson as VP, Head of QualityPharnext SA announces the appointment of Scott Johnson as VP, Head of Quality. This appointment further strengthens the Company's Senior Leadership Team. Scott has more than 15 years of experience in quality management and compliance within the healthcare sector. He joins from Oyster Point Pharma, where he was Head of Quality Assurance. There, he established and implemented a comprehensive quality management system and oversaw all quality-related functions during the submission of an NDA application and successful launch of Oyster Point's first commercial product. Prior to Oyster, Scott served as Director, Quality Assurance at Lupin Pharmaceuticals where he had overall responsibility for quality and compliance. He has also held roles at Johnson & Johnson and Warner Chilcott. Scott has a BA in Organizational Management from the Eastern University, St. David's, PA and previously served in the United States Navy. At Pharnext, Scott will continue to develop and maintain the Company's Quality strategy and ensure its operational execution. He will oversee the Quality activities in the areas of Manufacturing (Good Manufacturing Practices), Laboratory (Good Laboratory Practices) and Clinical (Good Clinical Practices) to ensure compliance with regulatory requirements. Scott will also be responsible for promoting a quality mindset across the Company and working with cross-departmental leadership to ensure the delivery of high-quality products and services.
Board Change • Nov 16No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 8 non-independent directors. Director Hugo Brugiere was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.
Reported Earnings • Oct 18First half 2022 earnings releasedFirst half 2022 results: Net loss: €19.1m (loss widened 41% from 1H 2021). Revenue is forecast to stay flat during the next 2 years compared to a 17% growth forecast for the Biotechs industry in Germany.
Board Change • Apr 27Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 10 non-independent directors. Independent Non-Executive Director Piers Morgan was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Oct 16First half 2021 earnings releasedFirst half 2021 results: Net loss: €13.6m (loss widened 49% from 1H 2020).
Reported Earnings • Apr 30Full year 2020 earnings releasedFull year 2020 results: Net loss: €21.6m (loss narrowed 7.5% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1